HC Wainwright Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $61.00

Tarsus Pharmaceuticals (NASDAQ:TARS - Free Report) had its price target upped by HC Wainwright from $57.00 to $61.00 in a research report released on Monday, Benzinga reports. They currently have a buy rating on the stock.

Several other analysts also recently issued reports on the stock. Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the company an outperform rating in a research report on Thursday. Jefferies Financial Group upped their target price on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a buy rating in a report on Wednesday, March 6th. Barclays lifted their price target on Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the company an overweight rating in a research note on Friday. Finally, The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a neutral rating in a research note on Thursday, February 29th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $50.38.

Tarsus Pharmaceuticals Stock Up 3.7 %

NASDAQ:TARS traded up $1.37 during trading hours on Monday, reaching $38.37. The company had a trading volume of 641,946 shares, compared to its average volume of 723,425. Tarsus Pharmaceuticals has a twelve month low of $12.57 and a twelve month high of $42.50. The company has a quick ratio of 7.92, a current ratio of 8.01 and a debt-to-equity ratio of 0.11. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -8.04 and a beta of 1.10. The business's 50-day simple moving average is $34.24 and its two-hundred day simple moving average is $26.49.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($1.31) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to the consensus estimate of $4.63 million. During the same period in the previous year, the firm earned ($0.49) earnings per share. On average, equities analysts expect that Tarsus Pharmaceuticals will post -4.05 earnings per share for the current year.

Insiders Place Their Bets

In related news, General Counsel Bryan Wahl sold 4,436 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the completion of the transaction, the general counsel now directly owns 40,951 shares in the company, valued at approximately $1,253,100.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, General Counsel Bryan Wahl sold 4,436 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the transaction, the general counsel now owns 40,951 shares of the company's stock, valued at $1,253,100.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Bobak R. Azamian sold 10,415 shares of Tarsus Pharmaceuticals stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $318,699.00. Following the sale, the chief executive officer now directly owns 26,456 shares of the company's stock, valued at approximately $809,553.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,496 shares of company stock valued at $749,578. Company insiders own 11.54% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Swiss National Bank lifted its position in Tarsus Pharmaceuticals by 1.4% during the first quarter. Swiss National Bank now owns 42,433 shares of the company's stock valued at $1,542,000 after purchasing an additional 600 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Tarsus Pharmaceuticals by 22.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company's stock valued at $92,000 after purchasing an additional 824 shares in the last quarter. Callan Capital LLC lifted its stake in Tarsus Pharmaceuticals by 11.5% during the fourth quarter. Callan Capital LLC now owns 16,950 shares of the company's stock worth $343,000 after purchasing an additional 1,750 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Tarsus Pharmaceuticals by 65.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company's stock worth $94,000 after purchasing an additional 2,092 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Tarsus Pharmaceuticals by 11.5% during the 4th quarter. Janney Montgomery Scott LLC now owns 24,227 shares of the company's stock valued at $491,000 after purchasing an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.